Skip to content
Open access

Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis

Oct 2026 · European Journal of Neurology · Vol 33 · 0 citations · 17 references
Medicine

Abstract

Highly effective (HE) disease‐modifying therapies (DMTs) reduce relapse‐associated worsening (RAW) and progression independent of relapse activity (PIRA). Natalizumab (NTZ) and anti‐CD20 agents show similar efficacy on relapse suppression, but long‐term comparative data on PIRA are limited. We aimed to compare PIRA accrual in relapsing–remitting MS (RRMS) patients treated with NTZ and anti‐CD20 drugs over a long follow‐up.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.